ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Saad Usmani, MD, on Daratumumab as Monotherapy for Multiple Myeloma

For a heavily pretreated multiple myeloma population, daratumumab as a monotherapy showed meaningful, durable activity with deep responses and a favorable safety profile. Saad Usmani, MD, of the Levine Cancer Institute, provides the highlights of this study on the first monoclonal antibody to show promise in multiple myeloma (Abstract LBA8512).

Sarcoma

Patrick Schöffski, MD

Patrick Schöffski, MD, on Eribulin for Soft-Tissue Sarcomas

Patrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).

Breast Cancer

Andrew D. Seidman, MD, and Clifford A. Hudis, MD

Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis

Clifford A. Hudis, MD, and Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discuss the use of the decision support system Watson for Oncology and results of the iCanCare study on second opinions (Abstracts 566 and 6508).

Skin Cancer

Claus Garbe, MD

Claus Garbe, MD, Summarizes Results of the DECOG Trial on SLNB-Positive Melanoma

Claus Garbe, MD, of the University of Tuebingen, discusses the survival of sentinel lymph node biopsy–positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).

Breast Cancer

Maura N. Dickler, MD and Clifford A. Hudis, MD

Maura N. Dickler, MD, and Clifford A. Hudis, MD, on Results From the CALGB Alliance Trial on Hormone Receptor–Positive Advanced Breast Cancer

Clifford A. Hudis, MD, and Maura N. Dickler, MD, of Memorial Sloan Kettering Cancer Center, discuss adding bevacizumab to letrozole as a first-line endocrine therapy for treatment of hormone receptor–positive advanced breast cancer (Abstract 501).

Feb

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Saad Usmani, MD, on Daratumumab as Monotherapy for Multiple Myeloma

Patrick Schöffski, MD, on Eribulin for Soft-Tissue Sarcomas

Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis

Claus Garbe, MD, Summarizes Results of the DECOG Trial on SLNB-Positive Melanoma

Maura N. Dickler, MD, and Clifford A. Hudis, MD, on Results From the CALGB Alliance Trial on Hormone Receptor–Positive Advanced Breast Cancer

Multidisciplinary Radiopharmaceutical Therapy Symposium: Highlights From the Inaugural New Meeting From ASTRO

High Response Rates With Front-Line Pivekimab Sunirine in BPDCN

Genetics Pioneer Zsofia Stadler to Lead JCO Precision Oncology

Does Diabetes Increase Pancreatic Cystic Neoplasm Risk

Topline PFS Results From BREAKWATER in mCRC Newly Announced